Fluoxetine
"Fluoxetine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
| Descriptor ID |
D005473
|
| MeSH Number(s) |
D02.092.831.280
|
| Concept/Terms |
Fluoxetine- Fluoxetine
- Fluoxetin
- N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
|
Below are MeSH descriptors whose meaning is more general than "Fluoxetine".
Below are MeSH descriptors whose meaning is more specific than "Fluoxetine".
This graph shows the total number of publications written about "Fluoxetine" by people in this website by year, and whether "Fluoxetine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1988 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluoxetine" by people in Profiles.
-
De Los Reyes A, Alfano CA, Beidel DC. The relations among measurements of informant discrepancies within a multisite trial of treatments for childhood social phobia. J Abnorm Child Psychol. 2010 Apr; 38(3):395-404.
-
Alfano CA, Pina AA, Villalta IK, Beidel DC, Ammerman RT, Crosby LE. Mediators and moderators of outcome in the behavioral treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2009 Sep; 48(9):945-53.
-
Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend. 1998 May 01; 50(3):221-6.
-
Salgado-Commissariat D, Alkadhi KA. Serotonin inhibits epileptiform discharge by activation of 5-HT1A receptors in CA1 pyramidal neurons. Neuropharmacology. 1997 Nov-Dec; 36(11-12):1705-12.
-
Alkadhi KA, Salgado-Commissariat D, Hogan YH, Akpaudo SB. Induction and maintenance of ganglionic long-term potentiation require activation of 5-hydroxytryptamine (5-HT3) receptors. J Physiol. 1996 Oct 15; 496 ( Pt 2):479-89.
-
Young CS, Mason R, Hill SJ. Studies on the mechanism of histamine-induced release of noradrenaline and 5-hydroxytryptamine from slices of rat cerebral cortex. Biochem Pharmacol. 1988 Jul 15; 37(14):2799-805.